Case Control Study
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Mar 26, 2022; 10(9): 2700-2709
Published online Mar 26, 2022. doi: 10.12998/wjcc.v10.i9.2700
Associations between coagulation factor XII, coagulation factor XI, and stability of venous thromboembolism: A case-control study
Yan Meng, You Li, Yan-Jun Ye, Qiang Ma, Jun-Bo Zhang, Hao Qin, Yang-Yang Deng, Hong-Yan Tian
Yan Meng, You Li, Qiang Ma, Jun-Bo Zhang, Hao Qin, Yang-Yang Deng, Hong-Yan Tian, Department of Peripheral Vascular Diseases, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, Shannxi Province, China
Yan-Jun Ye, Department of Breast and Thyroid Surgery, Baoji People’s Hospital, Baoji 721000, Shannxi Province, China
Author contributions: Meng Y, Li Y, Deng YY and Tian HY conceived and designed research; Ye YJ, Ma Q, Zhang JB and Qin H collected data and conducted research; Meng Y and Li Y analyzed and interpreted data, wrote the initial paper; Deng YY and Tian HY revised the paper; Tian HY had primary responsibility for final content; and all authors read and approved the final manuscript.
Supported by the Fund for Key Research and Development Program Project of Shannxi Province, No. 2017SF-254.
Institutional review board statement: The protocol of the study was approved by the Ethics Committee of the First Affiliated Hospital of Xi’an Jiaotong University before this study was carried out (number: XJTU1AF2018LSK-010). All procedures performed in studies involving human participants were in accordance with the ethics standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethics standards.
Informed consent statement: All included patients provided written informed consent before enrollment in the study.
Conflict-of-interest statement: The authors declare that they have no potential conflicts of interest.
Data sharing statement: The datasets generated and analyzed during the current study are available from the corresponding author on reasonable request.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hong-Yan Tian, MD, Director, Department of Peripheral Vascular Diseases, The First Affiliated Hospital of Xi'an Jiaotong University, No. 277 Yanta Road, Xi'an 710061, Shannxi Province, China. hongyantian417@163.com
Received: July 15, 2021
Peer-review started: July 15, 2021
First decision: October 18, 2021
Revised: October 29, 2021
Accepted: February 19, 2022
Article in press: February 19, 2022
Published online: March 26, 2022
Processing time: 250 Days and 4.4 Hours
Core Tip

Core Tip: In this case-control study, we found that plasma level of factor XI (FXI:Ag) was significantly higher in patients with deep venous thrombosis (DVT), and pulmonary embolism (PE) compared with those with only DVT. In addition, using the 95th percentile of FXI:Ag as cut-off values, a higher plasma level of FXI:Ag was associated with unstable DVT, as shown by the prevalence of PE in patients with DVT. Since the majority of PE is caused by thrombus that falls out from unstable DVT, these findings might suggest that a higher plasma level of FXI:Ag could be a marker for unstable DVT.